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ABSTRACT: An azide-functionalized 12-armed Buckminster
fullerene has been monosubstituted in organic media with a
substoichiometric amount of cyclooctyne-modified oligonucleo-
tides. Exposing the intermediate products then to the same
reaction (i.e., strain-promoted alkyne−azide cycloaddition,
SPAAC) with an excess of slightly different oligonucleotide
constituents in an aqueous medium yields molecularly defined
monofunctionalized spherical nucleic acids (SNAs). This proce-
dure offers a controlled synthesis scheme in which one oligonucleotide arm can be functionalized with labels or other conjugate
groups (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTA, and Alexa-488 demonstrated), whereas the rest of the 11
arms can be left unmodified or modified by other conjugate groups in order to decorate the SNAs’ outer sphere. Extra attention has
been paid to the homogeneity and authenticity of the C60-azide scaffold used for the assembly of full-armed SNAs.
■ INTRODUCTION
Spherical nucleic acids (SNAs, introduced originally by the
Chad Mirkin laboratory) consist of an appropriate core (gold,
silica, liposomes, proteins) and densely packed oligonucleotide
(ON) chains.1−7 They share many beneficial properties that
overcome some of the major shortcomings perceived for
therapeutic ONs: they have efficient free cellular uptake via
class A scavenger receptor-mediated endocytosis (which
correlates with the density and chemistry of the component
ONs),8,9 they have muted innate immune responses and
resistance to nuclease degradation (due to steric reasons), and
they are large enough to avoid renal clearance. The cellular
uptake occurs via an endosomal pathway,8−10 and SNAs are
able to silence target RNAs via steric blocking, once they enter
into the cytoplasm.11 Also, small interfering RNAs (siRNAs)
can work in spherical formulation. Dicer is able to cleave
siRNAs from SNAs and release them for the canonical RNA
interference pathway.12 Most of the reported SNAs are
polydisperse structures. The polydispersity may be a short-
coming as the data shows a similar behavior, but still a
population of particles lacking thorough characterization of the
molecules exists, something that is readily accessible for
covalent ON conjugates. Recently, a molecular SNA, based on
a Buckminster C60-fullerene core, has been described.
13 This
structure, consisting of antisense ON sequences on the C60
core, was dense enough to induce scavenger receptor-mediated
endocytosis. The internalization of these particles to breast
cancer (MCF7) cells was determined to be ca. 500-fold
compared to the free component ONs. Regulation of protein
expression by an antisense ON that targeted human epidermal
growth factor receptor 2 (HER2) mRNA transcripts was also
demonstrated.
Our interest in molecularly defined SNAs is to apply them as
delivery vehicles together with the covalent conjugation
strategy. The rationale of this idea is that radial formulation
could be a simple option to emphasize the ligand-specific effect
on the outer sphere of the SNAs and at the same time hide the
unfavorable distribution properties of negatively charged
ONs.14−17 For the monitoring of cellular uptake and
biodistribution of these decorated SNAs, appropriate labeling
is needed, which may cause a misleading distribution and
cellular delivery of the actual structure (if all arms are labeled).
Therefore, to keep the label effect minimal, an established
method that allows controlled monofunctionalization of the
SNAs is valuable. Furthermore, the controlled monofunction-
alization can be utilized to integrate SNAs specifically with
other delivery vehicles. In the present study, an azide-
functionalized 12-armed Buckminster fullerene (1) is exposed
to a substoichiometric amount of cyclooctyne-modified and
-labeled (DOTA and Alexa 488) ONs, which gave the
monofunctionalized fullerene in relatively high yields. The
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isolated intermediate products were then exposed to an excess
of slightly different ON constituents in an aqueous medium,
which gave the monolabeled full-armed SNAs. This two-step
process was noticed to be crucial, not only for the controlled
assembly but also for the preparation of the C60-based SNAs in
more general, as the solubility properties of the lipophilic C60
core and hydrophilic ONs severely retard the full decoration in
one reaction medium only. Reverse-phase high-performance
liquid chromatography (RP-HPLC), native polyacrylamide gel
electrophoresis (PAGE), capillary electrophoresis (CE), MS
spectroscopy, dynamic light scattering (DLS), and size
exclusion chromatography equipped with a multiple-angle
light-scattering detector (SEC-MALS) were used to analyze
the end products. We also paid extra attention to the
homogeneity and authenticity of the initial C60-azide scaffold
(1) as it is readily contaminated by a hardly distinguishable
azide-C60 [3 + 2] cycloaddition side product that would
hamper the assembly, purification, and identification of the
target SNAs. Overall, this procedure allows a controlled
synthesis scheme in which one of the ON arms of SNAs can be
selectively functionalized with labels or other conjugate groups.
In one case, D-galactose-conjugated ONs were used to decorate
the outer sphere. In addition, radiolabeling of a DOTA-labeled
SNA has been demonstrated.
■ RESULTS AND DISCUSSION
Synthesis and Purification of the C60-Azide Core (1).
The C60-azide scaffold (1) was synthesized following a
previously published procedure (Scheme 1).13 However, in
our hands, Bingel’s cyclopropanation18,19 between Buckmin-
ster fullerene (C60) and bis(2-(2-(2-(2-azidoethoxy)ethoxy)-
ethoxy)ethyl)malonate gave a mixture of compounds (1 and 2,
ca. 1:1, n/n) with equal molecular masses and similar NMR
data (2 with markedly broader resonances, A vs B in Scheme
1). Repeated column chromatography and RP-HPLC
purification were needed to obtain the homogenized 1 in
15% overall isolated yield, which was used for the preparation
of SNAs. In order to provide further understanding of the
products’ identity and applicability for the SNAs’ assembly,
preliminary SPAAC trials were carried out: Both 1 and 2 were
exposed to an excess of bicyclo[6.1.0]non-4-yn-9-ylmethanol-
and 5′-2-(bicyclo[6.1.0]non-4-yn-9-yl)ethylphosphate (BCN)-
modified T6 sequence (ON1, following the two-step process in
Scheme 2). MS (ESI-TOF) analysis verified that all 12 arms of
1 could be readily functionalized, but reactions with 2 stacked
to undecafunctionalized products (Figures S6 and S7).
1H−15N heteronuclear multiple bond correlation (HMBC)
analysis was used to further verify the authenticity of 2, which
revealed that part of the nitrogen signals was characteristic to
triazol and not entirely to alkylazide (Figures S8 and S9). The
fact that the [3 + 2] cycloaddition occurred upon Bingel’s
cyclopropanation is understandable, as this reaction has been
used to functionalize the C60 core in very similar
conditions.20−24 For further evidence, ad hoc-synthesized
triazolino fullerenes were synthesized by treating C60 with 2-
(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanol. The NMR sig-
nals of the triazolino fullerenes (di-, tri-, and tetrafunctional-
ized products obtained, Scheme S1) were comparable to trace
signals of 2.
Synthesis of Oligonucleotides. For the assembly of
SNAs (S1−S6), BCN-modified ONs (ON1−ON3, ON5, and
ON7−ON10, Scheme 2) were synthesized using an automated
DNA/RNA synthesizer. A standard phosphoramidite coupling
cycle and commercially available 2′-O-methylribonucleotide
and 2′-deoxyribonucleotide building blocks were used for the
assembly. 3-Phenyl 1,2,4-dithiazoline-5-one (POS) was used as
a sulfurization reagent for the synthesis of ON5. Our
previously reported customized solid supports25,26 were
utilized for the synthesis of appropriately 3′-modified ONs:
ON7 and ON10 with a 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) and a D-galactose moiety,
respectively. While ON1 and ON2 are short sequences,
Scheme 1. 1H NMR (500 MHz, CDCl3) Spectrum of 1 (A) and 2 (B)
a
aConditions: (i) bis(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)malonate, CBr4, 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU), o-dichlorobenzene
under argon, 3 days at room temperature.
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preliminarily used to demonstrate the SNA’s assembly (S1 and
S2), ON3−ON10 are biologically active sequences. ON3 (and
ON4) is an antisense sequence that targets HER2 mRNA
transcripts. Its biological activity in SNA formulation has
previously been demonstrated.13 The phosphorothioate (PS)
sequence of ON5 (and ON6) is a splice switching ON that
prevents expression of an androgenic receptor variant (AR-V7)
in prostate cancer cells.27 The 2′-O-methylated sequence
found in ON7, ON9, and ON10 is complementary to micro-
RNA 15b that is involved in hepatocyte apoptosis.28,29 We
have previously 68Ga labeled this same ON and its
glycoconjugates and studied their biodistribution by in vivo
positron emission tomography/computed tomography (PET/
CT) imaging.30−32
Controlled Assembly of Monofunctionalized SNAs on
the C60-Azide Core. In initial trials, the C60-azide core 1 was
dissolved in a minimum volume of DMSO and treated with an
excess (>12 equiv) of BCN-modified oligonucleotides in an
aqueous solution containing 1.5 M NaCl.13 However, the
drastically different solubility properties between the lipophilic
C60-azide core (1) and the hydrophilic ONs retarded the
SPAAC conjugation, and complex mixtures of products were
obtained (reactions using different DMSO−H2O ratios,
different spacers between the ONs and the core, BCN- vs
dibenzocyclooctyne-modified ONs, and different temperature
were attempted). This guided us to try a two-step process in
which 1 was first conjugated with ONs in DMSO, and once
the partially functionalized more hydrophilic intermediate
products were obtained, the reaction was changed to an
aqueous medium to yield full-armed SNAs. Interestingly,
monofunctionalization proceeded in DMSO (Figure 1A,
Scheme S2) with a reasonable excess of 1, which could be
utilized for the controlled assembly of heteroantennary SNAs
(S1--S6, Scheme 2). In optimized conditions (Scheme 2),
BCN-modified ONs (ON1−3, ON5, and ON7) were treated
with 5 equiv of 1 in DMSO to yield monofunctionalized C60−
Scheme 2a
aConditions: (i) BCN-modified oligonucleotide 1 (5 equiv) in DMSO, overnight at 25 °C, (ii) AF-488 NHS ester, 0.1 M sodium borate (pH 8.5),
overnight at 25 °C, (iii) C1−C7, BCN-modified oligonucleotide (1.2 equiv/arm) in aqueous 1.5 M NaCl, 3 days at 25 °C.
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ON conjugates (C1−C3, C5, and C7) in relatively high RP-
HPLC-isolated yields (45−50%). The remaining excess of 1
could be reisolated (cf. Figure 1A) and reused. The amino-
modified conjugates (C3 and C5) were labeled with Alexa-
488-N-hydroxysuccinimide (NHS) ester, and the conjugates
(C1, C2, C4, C6, and C7) were then dissolved in aqueous 1.5
M NaCl solution and mixed with a slight excess (12 equiv) of
BCN−ONs (ON1, ON5, and ON8−ON10).33−35 After
incubation for 2 days at room temperature, one additional
equivalent of BCN−ONs was added to confirm the completion
of the full decoration (in overall 1.2 equiv/arm). The reaction
mixtures were then incubated one more day (3 days total) and
subjected as such to RP-HPLC (Figure 1C, Scheme S2). The
obtained SNAs (S1−S6) were isolated in 40−57% yield
according to UV absorbance at 260 nm (S1, S2, S5, and S6)
and 488 nm (S3 and S4).
Characterization of the SNAs. The homogeneity and
identity of the RP-HPLC-isolated SNAs were evaluated by
PAGE, CE, SEC-MALS, and MS-ESI spectroscopy. As seen on
PAGE (Figure 2B), each SNA resulted in a distinct and
relatively sharp band. The stereoisomeric phosphorothioate
backbone of S4 caused a blurred band compared to other
SNAs. On the electrophoregrams of larger SNAs (S5 and S6),
faster eluting trace products (<5% of the total intensity) could
be additionally observed that indicated incomplete decoration.
Fractionation by RP-HPLC (Figure 1C) did not affect the
results on PAGE, neither did the prolonged reaction time nor a
higher excess of BCN-ONs (ON9 and ON10) used for the
SPAAC conjugation. Despite these traces of side products
(most likely 11-armed SNAs), the overall purity of the
assembled SNAs after single RP-HPLC purification proved
relatively high on PAGE. Next, the applicability of CE to
evaluate the homogeneity of the SNAs was demonstrated
(Figure 2A and Scheme S2). CE could not discriminate traces
of incomplete (11-armed) products from the full-armed SNAs,
but it proved to be a valuable tool to confirm the absence of
smaller component ONs. SEC-MALS is a common technique
employed to estimate the homogeneity, aggregation tendency,
Figure 1. (A and C) Examples of RP-HPLC profiles of crude product (C7 and S5) mixtures. (B) Example of the MS-ESI spectrum of purified
monosubstituted C60-ON-conjugate (C7). (D) Example of the RP-HPLC profile of purified SNA (S5).
Figure 2. (A) Example of capillary electrophoregrams (CE) of purified SNA (S5). (B) Polyacrylamide gel electrophoregrams (PAGE) of purified
SNAs (S1−S6). (C) Example of the SEC-MALS profile of purified SNA (S5) used to evaluate the molecular mass. For the conditions, see
Experimental Section.
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and molecular weight of biomolecules.36 This is particularly
useful for large molecular weight compounds (>100 kDa),
characterization of which is often hardly accessible by MS
spectroscopy. This was the case also with SNAs. Acceptable m/
z data (a spectrometer equipped with a hybrid quadrupole
orbitrap and nano ESI ionization was used) could be obtained
for small model SNAs S1 and S2 (Figure S12), whereas humps
of overlapping multiply charged ion patterns, unsuitable for
reliable MS characterization, were obtained for S3−S6. In fact,
even S1 and S2 were prone to form stable multiple sodium
adducts (Figure S12), and the observed molecular masses were
0.1 and 0.2 kDa higher compared to the calculated values
(Table 1, entries 1 and 2). Therefore, we applied SEC-MALS
to estimate the molecular weights of S3−S5. The samples of
S3−S5 were eluted with 150 mM phosphate buffer (pH 7)
through a 300 Å, 2.7 μm, 4.6 × 300 mm SEC column. As seen
in Figure 2C and Figure S12, each SNA resulted in a major
peak (retention time ca. 7 min) that represented the 70−80%
mass fraction of the sample. The MALS-based estimation of
the molecular weights extracted from the major peaks matched
relatively well with the expected calculated values (Table 1,
entries 3−6). It may be worth mentioning that the errors of the
observed molecular masses were less than the molecular mass
of the component ONs. In each case, faster eluting fractions
(retention time ca. 5.0−6.5 min) were observed also, the
molecular weight of which (>200 kDa) may be attributed to
aggregation of the SNAs (Figure 2C and Figure S12).
Together with the molecular masses obtained for small
model SNAs S1 and S2 and the SEC-MALS-based character-
ization of SNAs S3−S6, the authenticity of the products could
be verified. Finally, the hydrodynamic diameter of the SNAs
was determined by DLS. The diameters (ranging from 9.2 to
21.4 nm, Table 1) of S1−S6 correlated with the lengths of the
component ONs.
Melting Analysis (Tm) and Titration of SNA with a
Complementary RNA Strand. In order to evaluate the
hybridization properties of the C60-based SNAs, UV-melting
profile experiments (Tm) and titration of S4 with a short model
sequence of AR-V7 pre-mRNA were carried out. The S4−
RNA duplex resulted in a −3 °C decrease in the Tm value when
compared to the corresponding free duplex (Figure 3A).
Furthermore, gentler melting profiles were observed, which
was more obvious, when fully hybridized S4 was compared to a
partially hybridized one (12 vs 6 equiv of complementary
strands). This indicates electrostatic repulsion/steric crowding
between the duplexes on fully loaded SNA (S4 + 12 equiv of
RNA). This observation is consistent with the previous
findings in which a retarded loading of siRNAs onto SNAs
has been observed.12,37−39 However, it is notable that the fully
loaded SNA (S4 + 12 equiv of RNA) was virtually stable below
the physiological temperature and the observed “’premature’”
partial denaturation occurred at a higher temperature.
Titration of S4 with the same complementary RNA verified
the correct stoichiometry of the melting profiles (Figure 3B;
note, the concentration of S4 was determined according to the
Alexa content). Gradual addition of the complementary RNA
strand increased the overall absorbance with a constant slope
(hypochromic effect due to the hybridization compensates for
the increased absorbance), and a turning point of the slope was
observed once the amount of the complementary RNA
exceeded the fully occupied SNA. The observed turning
point at 11.9 equivalents matched well with the correct 12-
armed SNA structure.
Radiolabeling. To evaluate the applicability of DOTA as a
68Ga-chelating agent on SNAs, S5 was used as a model in








S1 27.6 27.8a 9.2 ± 1.2
S2 27.6 27.7a 9.6 ± 2.5
S3 61.2 62.6 ± 0.4b 11.8 ± 0.6
S4 107.3 106.8 ± 3.6b 16.2 ± 0.1
S5 109.9 109.3 ± 2.1b 19.0 ± 2.0
S6 113.2 107.4 ± 2.3b 21.4 ± 0.8
aA hybrid quadrupole-orbitrap spectrometer with nano ESI-ionization
was used for mass analysis (cf. Figure S12). bThe values were
obtained by SEC-MALS-based estimation of the molecular mass (cf.
Figure 2C).
Figure 3. Melting profile analysis and titration of S4 with complementary RNA: C AAU GUC UCU CUU UCA UAC UAG. For the formation of
free duplex CUA GUA UGA AAG AGA GAC AUU G (2′-O-methyl RNA phosphorothioate) was used.
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preliminary radiolabeling experiments. With these small-scale
trials (1−2 nmol of S5) we also tried to find conditions that
minimize precursor loading at the expense of yield. Radio-
chemical yields of up to 68 MBq were achieved (24% decay
corrected yield). Radiochemical purity was measured at up to
69% as measured by PAGE and 73% by ultrafiltration (Figure
4). We observed that size exclusion purification of the reaction
mixture could not sufficiently remove all unbound 68Ga, even
when two successive column purifications were used. Also,
commonly used solid-phase extraction columns with C8, C18,
and hydrophobic lipophilic balance (HLB) solid phases were
attempted. Due to the difficulty of separating unbound 68Ga
and the low performance of the size exclusion purification, we
suspected unspecific binding of 68Ga to the SNA structure.
This was confirmed by incubating the end product (S5[68Ga])
in 50 mM ethylenediaminetetraacetic acid/phosphate-buffered
saline (EDTA/PBS) at pH 7.4 in 37 °C. As expected, we
observed a further 10% increase in the unbound activity
fraction after 1 h EDTA challenge, as measured by ultra-
filtration. This relatively stable unspecific 68Ga binding to the
densely packed ON construct is in agreement with the
behavior of the SNAs in MS in which relatively stable multiple
sodium adducts were observed (Table 1, entries 1 and 2).
Although the small-scale (1−2 nmol of precursor S5 loading)
experiments did not produce acceptable purities, valuable
information was obtained, which will aid future in vivo PET/
CT imaging studies of SNAs. Due to the unspecific 68Ga
binding observed, an indirect labeling method, such as a click
reaction with a reactive agent prelabeled with either 68Ga or
18F, may prove a more suitable choice for SNAs.40,41
■ CONCLUSION
A two-step procedure that allows controlled assembly of
monofunctionalized C60-based SNAs has been described. This
preliminary data opens the door for controlled decoration of
SNAs with labels or tissue/organ-specific ligands and
possibility integrating them specifically to other delivery
vehicles. Despite the multicomponent SPAAC-based assembly
and two RP-HPLC purifications, the overall yield of these
SNAs proved to be relatively high, ca. 20−30%. We also paid
extra attention to the homogeneity of the C60-azide scaffold
(1). 1 was noticed to be readily contaminated by a hardly
distinguishable azide-C60 [3 + 2] cycloaddition side product
(2) that would hamper the assembly, purification, and
identification of the SNAs. The homogeneity and authenticity
of the SNAs were evaluated by various methods, including RP-
HPLC, native PAGE, CE, SEC-MALS, and MS-ESI spectros-
copy. While PAGE was a superior technique to evaluate the
homogeneity of these C60-based SNAs, SEC-MALS could be
used for rough evaluation of the molecular weights.
Preliminary radiolabeling experiments suggested that the
chelation-based techniques should be replaced by a covalent
radiolabeling strategy to prevent unspecific metal ion (68Ga)
binding to the densely packed ON shell of these nanoparticles.
The described procedure with detailed analytical control of
each single step will expectedly promote design of new
molecularly defined monofunctionalized SNAs, which may find
interesting therapeutic and diagnostic applications.
■ EXPERIMENTAL SECTION
Synthesis and Purification of the C60-Azide Core (1). 1
was synthesized by Bingel cyclopropanation following the
previously published procedure:13 Buckminster fullerene C60
(0.40 g, 0.56 mmol) was dissolved in dry and degassed
(oxygen removed by bubbling with argon) o-dichlorobenzene
(140 mL). Bis(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-
malonate (2.8 g, 5.6 mmol, 10 equiv), CBr4 (19 g, 56 mmol,
100 equiv), and 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU, 1.7
mL, 11 mmol, 20 equiv) were added, and the mixture was
stirred 3 days at room temperature under argon. The mixture
was purified by silica gel column chromatography (pore size 60
Å, 230−400 mesh particle size, 40−63 μm particle size,
isocratic elution with 2% MeOH in dichloromethane, twice) to
yield the desired product 1 (0.66 g, 32%) and a near identically
behaving side product 2 (0.65 g, 31%, for further character-
ization, see Figures S2−S9). A sample (30 mg) of column-
purified 1 was further purified by RP-HPLC to yield
homogenized 1 (7 mg, 23%, overall yield 15%), which was
used for the preparation of SNAs. 1: 1H NMR (500 MHz,
CDCl3) δ 4.43 (t, 24H, J = 4.1 Hz), 3.75 (t, 24H, J = 4.1 Hz),
3.69 (t, 24H, J = 4.3 Hz), 3.67 (s, 48H), 3.64 (s, 48H), 3.40 (t,
24H, J = 4.2 Hz); 13C NMR (125 MHz, CDCl3) δ 163.5,
145.8, 141.0, 70.7, 70.0, 69.0, 68.6, 65.8, 50.7, 45.2; MS (ESI-
TOF) molecular mass for C174H192N36O60Na3 3816.6, found
3816.4 (calculated from [(M + 3Na)/3]3+.
Synthesis of C60-ON Conjugates C1−C3, C5, and C7.
General procedure: BCN-modified oligonucleotide (ON1−3,
ON5, or ON7, 0.1 μmol in 60 μL of H2O) was slowly added to
a mixture of C60 core 1 (0.5 μmol in 540 μL of DMSO) in a
microcentrifuge tube. The reaction mixture was gently shaken
overnight at room temperature and subjected to RP-HPLC
(Figure 1A and Scheme S2). An analytical RP-HPLC column
(250 × 4.6 mm, 5 μm), a gradient elution from 40% to 100%
MeCN in 50 mmol L−1 triethylammonium acetate over 30
min, and detection at 260 nm were applied. The C60−ON
conjugate (C1−C7) and unreacted fullerene core 1 were
collected individually and lyophilized to dryness. The
authenticity of the products was verified by MS (ESI-TOF)
(Figure 1B and Figure S11). Isolated yields (45−50%, only
Figure 4. Representative polyacrylamide gel electrophoresis (PAGE)
autoradiography image and quantification of radiolabeled SNA
S5[68Ga].
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slight differences in yields between the different conjugates
observed) of C1−C7 were determined by UV absorbance at
260 nm.
Synthesis of Alexa-488-Labeled Conjugates C4 and
C6. AF488 NHS ester (0.4 μmol in 6 μL of DMSO) was
added to a buffered mixture of C60−ON conjugate (50 nmol of
C3 or C5 in 60 μL of 0.1 M sodium borate, pH 8.5). The
reaction mixture was gently shaken overnight at room
temperature and subjected to RP-HPLC. An analytical RP-
HPLC column (250 × 4.6 mm, 5 μm), a gradient elution from
40% to 100% MeCN in 50 mmol L−1 triethylammonium
acetate over 30 min, and detection at 260 nm were used. The
product fractions were collected and lyophilized to dryness.
The authenticity of the products (C4 and C6) was verified by
MS (ESI-TOF) (Figure S11). Isolated yields (C4, 32%; C6,
62%) of the products were determined by UV absorbance at
488 nm.
Assembly of SNAs (S1−S6). General procedure: C60−ON
conjugate (C1−C7, 20 nmol in 55 μL of H2O) was mixed with
BCN−ON (ON1, ON3, ON5, and ON8−ON10, 240 nmol in
145 μL of H2O), and 100 μL of 4.65 M NaCl was added. The
reaction mixture was gently shaken for 2 days at room
temperature, and then one additional equivalent of BCN−ON
was added. The mixture was then incubated one more day (72
h total using 1.2 equiv of BCN−ON/azide arm) and subjected
to RP-HPLC. An analytical RP-HPLC column Phenomenex,
Aeris 3.6 μm WIDEPORE XB-C18 200 Å, 150 × 4.6 mm, a
linear gradient from 5% to 60% MeCN in 50 mmol L −1
triethylammonium acetate over 40 min, a flow rate of 1.0 mL
min −1, and detection at 260 nm were used for purification
(Figure 1C and Scheme S2). The product (S1−S6) fractions
were collected and lyophilized to dryness. Isolated yields (40−
57%) of the products were determined by UV absorbance at
260 nm (S1, S2, S5, and S6) and 488 nm (S3 and S4). The
obtained SNAs were characterized by MS-ESI (equipped with
a hybrid quadrupole orbitrap and nano-ESI ionization) (S1
and S2) and SEC-MALS (S3−S6) (Table 1, Figure 2C, and
Figure S12). For the homogeneity and particle size evaluation
of S1−S6, see the PAGE (Figure 2B), CE (Figure 2A and
Scheme S2), SEC-MALS (Figure 2C, Scheme S2), and DLS
experiments described below.
PAGE Analysis of SNAs. Native 6% Tris base, boric acid,
EDTA, and acrylamide (TBE) gel were used to check SNAs’
purity. A precast gel cover (10 cm × 10 cm in size, Thermo
Fisher Scientific) was fixed into a vertical electrophoresis
chamber, and the running buffer (90 mM Tris, 90 mM borate,
and 2 mM EDTA, 8.3 pH) was filled into the chamber. SNA
samples (5 μL of 0.1 μM SNAs mixed with 5 μL of TBE
sample buffer) and a DNA ladder (100, 200···1000 bp; note,
the ladder is just used to confirm the quality and comparability
of the runs and cannot be used for size evaluation of the SNAs)
were loaded and electrophoresed at constant 200 V (45 mA)
for approximately 30 min. After completion of electrophoresis,
gel was removed from the chamber and the SNA bands were
monitored either directly by UV or after staining by SYBRTM
Gold Nucleic Acid Stain (Thermo Fisher Scientific).
Capillary Electrophoresis Experiments. Samples were
analyzed by capillary zone electrophoresis in a fused silica
capillary of 75 μm i.d. and 57 cm effective length. The
background electrolyte was 0.3 M citrate buffer, pH 3.1. A
voltage of 15 kV and pressure of 0.3 PSI were applied. UV
detection at λ = 260 nm was used.
SEC-MALS Experiments. SEC-MALS was performed
using an Agilent Technologies 1260 Infinity II HPLC system
(sampler, pump, and UV−vis detector) equipped with a Wyatt
Technologies miniDAWN light scattering detector and Wyatt
Technologies Optilab refractive index detector. An Agilent
AdvanceBio SEC 300 Å 2.7 μm 4.6 × 300 mm column and 150
mM sodium phosphate, pH 7.0, as mobile phase eluting at a
rate of 0.2 mL min−1 and run time of 20 min were used for
each experiment. For each run, 4 μL of sample with a SNA
concentration of 1 mg mL−1 in Milli-Q water was loaded onto
the pre-equilibrated column. Detector signals were aligned
with a bovine serum albumin (BSA) standard, which was
analyzed prior to SNA samples. The RI and MALS signals were
used for the MW calculations using an average refractive index
increment (dn/dc) of 0.1703 mL/g.
Melting Experiments (Tm) and Titration of S4 with a
Complementary RNA. The melting curves (absorbance vs
temperature) were measured at 260 nm on a UV−vis
spectrometer equipped with a multiple cell holder and a
Peltier temperature controller. The temperature was changed
at a rate of 0.5 °C min−1 between 10 and 80 °C. The
measurements were performed in 10 mmol L−1 sodium
cacodylate (pH 7.0) with 0.1 mol L−1 NaCl and 1.0 μmol
L−1 ON. Tm values were determined as the maximum of the
first derivative of the melting curve. The UV titration of S4
(absorbance vs equivalents of complementary RNA oligonu-
cleotide added) was performed in 10 mmol L−1 sodium
cacodylate (pH 7.0) with 0.1 μmol L−1 NaCl and 63 nmol L−1
S4. RNA oligonucleotide with a complementary sequence to
S4 was added gradually in the solution, and the total
absorbance at 260 nm was monitored with an UV−vis
spectrometer. The sequence of complementary RNA was C
AAU GUC UCU CUU UCA UAC UAG. For the formation of
free duplex, CUA GUA UGA AAG AGA GAC AUU G (2′-O-
methyl RNA phosphorothioate) was used.
DLS Experiments. The size of the SNAs was measured at
room temperature using a Zetasizer Nano ZS90 (Malvern
Instruments Ltd., UK). The settings and conditions for the
measurements were as follows: material Protein (RI, 1.450;
absorption, 0.001), dispersant water (viscosity, 0,8872 cP; RI,
1.330) temperature was 20 °C, and equilibration time was 60 s.
Each sample (10 μg of SNA in 100 μL of aqueous 10 mmol
L−1 PBS, 2.7 mmol L−1 M KCl, 0.137 mol L−1 NaCl, pH 7.4)
was measured three times.
Radiolabeling Experiments. [68Ga]GaCl3 was eluted
from an IGG-100 68Ge/68Ga generator with 0.1 M HCl
through a Strata SCX cartridge into a waste container. The
cartridge was then eluted with 300 μL of 1.0 M sodium
chloride/0.1 M HCl solution, and an aliquot (200 μL) was
transferred to a reaction vial preloaded with a mixture of
HEPES (12 mg) and S5 (1−2 nmol) in 50 μL of water.
Gentisic acid (10 μL, 0.1 M in water) was added as a radical
scavenger to counter possible radiolysis. The reaction mixture
was then incubated at 70 °C for 15 min. The mixture was
cooled on ice after incubation and purified using consecutive
Illustra NAP-5 and NAP-10 size-exclusion columns (Cytiva,
USA) equilibrated with phosphate-buffered saline (PBS, pH
7.4). This afforded the end product formulation in 1.2 mL of
phosphate-buffered saline (PBS). Radiochemical purity was
determined by native PAGE and ultrafiltration. PAGE was
carried out with TBE-buffered 6% polyacrylamide gels in a
Biorad miniprotean II system (Bio-Rad Laboratories, Hercules,
CA, USA) ran at 250 V. The gels were developed on BAS-
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TR2025 phosphor imaging plates and analyzed with a BAS-
5000 scanner (Fuji, Tokyo, Japan). Ultrafiltration was done in
triplicate by loading 0.5 mL, 30 kDa Microcon filters
(Millipore, Bedford, MA, USA), with 100 μL of PBS and 1
μL of reaction mixture. The filters were centrifuged three times
for 5 min at 14 000g, with addition of 100 μL of PBS between
spins. The activities of the filter and the filtrate were measured
with a 1480 Wizard gamma counter (PerkinElmer/Wallac,
Turku, Finland), and the purity was calculated by dividing the
filter activity by the total activity.
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